ARF6 and uveal melanoma: Mutations in GNAQ and CYSTR2 represent the vast majority of uveal melanoma tumors and they activate downstream targets such as TRIO or ARF6. Inhibitors of these two proteins have been developed, and it would make sense to test them in uveal melanoma [92,93,94]